FDA Approvals, News & UpdatesLung CancerNewsworthy

Tagrisso Now Approved as First Treatment for Metastatic NSCLC and EGFR Mutations

May 2018 – Cancer Biomarkers and Molecular Testing

On April 18, 2018, the FDA approved Tagrisso (osimertinib; from AstraZeneca) as the first treatment for patients with metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

Patients who received Tagrisso had a longer period (18.9 months) without cancer progression versus 10.2 months with Iressa (gefitinib) or Tarceva (erlotinib). Among the patients who responded to treatment, the average duration of response was 17.6 months with Tagrisso versus 9.6 months with Iressa or Tarceva.

The most common side effects with Tagrisso are diarrhea, rash, dry skin, and decreased appetite.

Share this:

Recommended For You
Lung CancerIssue Introductions
Looking at Lung Cancer without Stigma
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
In her introduction to this special issue on Lung Cancer, Lillie Shockney, RN, BS, MAS, emphasizes that we need to inspire and help people to stop smoking, and get rid of the overall stigma surrounding this disease.
Patient StoriesLung CancerPatient Advocacy
Becoming a Patient Advocate After a Small-Cell Lung Cancer Diagnosis at Age 28
By Montessa Lee
Montessa Lee’s pain persisted after an initial visit to the doctor and a misdiagnosis. Finally, an x-ray in the emergency room revealed a 15-cm mass on her left lung. Read how she turned anger into action.
Lung CancerImmunotherapyBiomarkers
Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
By Wayne Kuznar
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC.
Last modified: June 28, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Race or Ethnicity
Profession or Role
Primary Interest